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Omalizumab (OMA), a humanized anti-immunoglobulin
E (IgE) monoclonal antibody was approved in the EU in
2005 as an add-on therapy for patients with severe persis-
tent allergic asthma (AA). We present an overview
of recent developments in the use of OMA for this
indication.
Approval for pediatric use: followed the completion of
two clinical trials in children 6 to <12 years of age with
moderate-to-severe AA, who were either well- or inade-
quately controlled with inhaled corticosteroids (CS).
Pooled analysis of these data demonstrated the efficacy
and safety of OMA and led to approval in the EU for use
in this population.
Expansion of the dosing table (DT)
The initial DT applied to patients with IgE levels between
30–700 IU/ml and body weight up to 150 kg, with a maxi-
mum dose of 375 mg per administration. The DT was
expanded to enable treatment of patients with levels up to
1,500 IU/ml, with a maximal dose of 600 mg per adminis-
tration. Subsequent pharmacokinetic (PK) and pharmaco-
dynamic (PD) modelling and simulation predicted that
some doses could be doubled and given less frequently,
while maintaining efficient suppression of free IgE without
compromising safety. The DT was further revised and
approved in the EU in 2012, simplifying the dosing sche-
dule in a subset of patients (225–300 mg every 2 weeks) to
receive treatment at double the dose every 4 weeks. Devel-
opment of a pre-filled syringe: A more concentrated liquid
formulation may eliminate a potential source of error dur-
ing dosing and simplify drug administration. A PK/PD
study demonstrated bioequivalence and a similar safety
and tolerability profile between the liquid formulation and
the lyophilized powder.
OMA safety update
A pooled analysis of 32 trials showed no association
between treatment and risk of malignancy (rate ratio 0.93
[95% CI, 0.39–2.27]). In an interim analysis of an observa-
tional study (N=8,023), the malignancy incidence was
similar in both cohorts (+/-OMA). OMA ‘real-life’ 2-year
registry (N=943): Efficacy results demonstrated an increase
in the number of patients free from clinically significant
exacerbations following OMA treatment (6.8% at baseline
to 67.3% at 24 months). A reduction in maintenance oral
CS use to 14.2% after 24 months compared with 28.6% at
baseline and, improvements in asthma control and quality
of life were also observed. Such advances in the use of
OMA may benefit a wider range of patients with severe
AA and address unmet needs in asthma treatment.
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